OYST News and Press, Oyster Point Pharma Inc. From 11/04/21

Oyster Point Pharma (NASDAQ:OYST): Q3 GAAP EPS of -$0.68 beats by $0.48. Revenue of $17.94M Press Release As of September 30, 2021, cash and cash equivalents were $184.2M, compared to $192.6M as of December 31, 2020. For further details see: Oyster Point Pharma EPS beats by $0.48 ...

FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 Field Force Onboarding Completed During Q3’21, U.S. Launch of TYRVAYA Nasal Spray Initiated on Nov. 1 st ....

Oyster Point has launched a patient support program called TEAMTyrvaya™ TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease PRINCETON, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma...

Oyster Point Pharma (NASDAQ:OYST) announces that TYRVAYA (varenicline solution) Nasal Spray 0.03 mg is now available at U.S. regional wholesalers for distribution to pharmacies. The U.S. FDA had approved TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye...

TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease TYRVAYA is designed to activate the trigeminal parasympathetic pathway resulting in increased production of basal tear film as a treatment for dry eye disease ...

PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced mult...

PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced ...

Shares of Oyster Point Pharma (NASDAQ: OYST) were sinking 9.2% as of 11:05 a.m. EDT on Tuesday. The decline came only a day after the company won U.S. Food and Drug Administration (FDA) approval for its Tirvaya nasal spray in treating dry-eye disease. That FDA decision was defin...

Gainers: AlloVir (NASDAQ:ALVR) +14%, InflaRx (NASDAQ:IFRX) +14%, Harmony Biosciences (NASDAQ:HRMY) +13%, Omeros (NASDAQ:OMER) +11%, Prelude Therapeutics (NASDAQ:PRLD) +11%. Losers: Galera Therapeutics (NASDAQ:GRTX) -68%, Atea Pharmaceutic...

ION Geophysical (NYSE:IO) +45% sees Q3 revenues more than doubling Q/Q Valneva SE (NASDAQ:VALN) +36% after topline results from late-stage VLA2001 COVID-19 trial Adamis Pharmaceuticals (NASDAQ:ADMP) +35% after FDA approves opioid overdose treatment ZIMHI MeiraGTx...